Todd V. Brennan, MD, MS, FACS
Cedars-Sinai Comprehensive Transplant Center
8900 Beverly Blvd.
Los Angeles, CA 90048
Todd V. Brennan, MD, MS, FACS
- Surgery-General Surgery
- Surgery/Transplant Surgery
Kidney Transplants - Pediatric
The research of Dr. Brennan focuses on how tissue injury causes inflammation and how this inflammation relates to rates of rejection of transplanted organs. Overall, the context in which transplanted organs are encountered by our immune cells is critical to determining the immune response against them. In the setting of tissue injury occurring during organ procurement, storage and transplantation, the immune system is alerted to the presence of tissue damage and initiates a response to this injury. In other words, the immune system recognizes danger signals released by the transplanted organ and can respond aggressively, attacking and damaging the organ. The goal of Dr. Brennan’s research is to identify the molecules that create these signals and develop methods to prevent their release or block their recognition.
- Undergraduate: UCLA, 1994
- Medical School: Harvard Medical School, 1999
- Internship: University of California, San Francisco Medical Center, 2000
- Residency: University of California, San Francisco Medical Center, 2007
- Fellowship: University of California, San Francisco Medical Center, 2009
Awards & Activities
- Career Development Award (NIAID), National Institutes of Health, 2012
- Basic Science Faculty Development Grant, American Society of Transplantation, 2010
- Career Development Award in Liver Transplantation, American Association for the Study of Liver Diseases, 2010
- Vanguard Award, American Society of Transplant Surgeons, 2010
- Novartis Fellowship in Transplantation, American Society of Transplant Surgeons, 2007
- Roche Laboratories Scientist Scholarship, American Society of Transplant Surgeons, 2004
- Young Investigator Award, American Transplant Congress, 2004
- Health Scholar, Duke University School of Medicine, 2016
- Clarence Gardner, M.D. Award, 2016
- Merck Index Award, 1994
Click here for a list of peer-reviewed publications.
- Pollara J, Edwards RW, Lin L, Bendersky VA, Brennan TV. Circulating mitochondria in deceased organ donors are assoicated with immune activation and early graft dysfunction. JCI Insight. 2018;3(15):e121622. https://doi.org/10.1172/jci.insight.121622.
- Barbas AS, Lin L, McRae M, MacDonald AL, Truong T, Yang Y, Brennan TV. Heparan sulfate is a plasma biomarker of acute cellular allograft rejection. PLoS One. 2018 Aug 7;13(8):e0200877. doi: 10.1371/journal.pone.0200877. PMID: 30086133
- Brennan TV, Yang Y. PD-L1 serves as a double agent in separating GVL from GVHD. J Clin Invest. 2017 May 1;127(5):1627-1630.
- Brennan TV, Lin L, Brandstadter JD, Rendell VR, Dredge K, Huang X, Yang Y. Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation. J Clin Invest. 2016 Jan;126(1):207-219.
- Brennan TV, Rendell VR, Yang Y. Innate immune activation by tissue injury and cell death in the setting of hematopoietic stem cell transplantation. Front Immunol. 2015 Mar 16;6:101.
- Brennan TV, Lin L, Huang X, Cardona DM, Li Z, Dredge K, Chao NJ, Yang Y. Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation. Blood. 2012 Oct 4;120(14):2899-2908.